<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Conflicting data exist on the role of antiplatelet agents in reducing incident <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> magnitude, but most prior studies used clinically-assessed neurologic deficit as the index of <z:hpo ids='HP_0001297'>stroke</z:hpo> extent rather than more precise volumetric measurements of <z:mpath ids='MPATH_124'>infarct</z:mpath> size </plain></SENT>
<SENT sid="1" pm="."><plain>We assessed the relation of premorbid antiplatelet use to initial diffusion-weighted MRI (DWI) lesion volumes among <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> patients </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Consecutive patients presenting within 24 h of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> over an 18-month period were studied </plain></SENT>
<SENT sid="3" pm="."><plain>DWI lesions were outlined using a semi-automated threshold technique </plain></SENT>
<SENT sid="4" pm="."><plain>Subjects were categorized into two groups: antiplatelet (AP) or no antithrombotic (NA) </plain></SENT>
<SENT sid="5" pm="."><plain>The relationship between prestroke antithrombotic status and DWI <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes was examined using multivariate quantile regression </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: One hundred sixty-six individuals met study criteria: 75 AP and 91 NA patients </plain></SENT>
<SENT sid="7" pm="."><plain>Median DWI volume was lower in the AP group than in the NA group (1.5 cc vs. 5.4 cc, p=0.031) </plain></SENT>
<SENT sid="8" pm="."><plain>A multivariable model (adjusting for age, history of <z:hpo ids='HP_0002326'>transient ischemic attack</z:hpo>, admission temperature, admission blood pressure, admission serum <z:chebi fb="105" ids="17234">glucose</z:chebi>, <z:hpo ids='HP_0001297'>stroke</z:hpo> <z:hpo ids='HP_0003674'>onset</z:hpo> to imaging interval, <z:hpo ids='HP_0001297'>stroke</z:hpo> mechanism, premorbid <z:chebi fb="0" ids="35664">statin</z:chebi> and <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> use) demonstrated smaller <z:mpath ids='MPATH_124'>infarcts</z:mpath> in the AP vs. NA group (adjusted volume difference: -1.3 cc, 95% CI=-0.09, -2.5, p=0.037) </plain></SENT>
<SENT sid="9" pm="."><plain>Prior <z:chebi fb="0" ids="35664">statin</z:chebi> use, no history of <z:hpo ids='HP_0002326'>TIA</z:hpo>, large vessel <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> and microvascular ischemic disease <z:hpo ids='HP_0001297'>stroke</z:hpo> mechanism were also independently associated with reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Prior antiplatelet treatment is independently associated with reduced cerebral <z:mpath ids='MPATH_124'>infarct</z:mpath> volume among <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> patients </plain></SENT>
<SENT sid="11" pm="."><plain>Premorbid <z:chebi fb="0" ids="35664">statin</z:chebi> use, <z:hpo ids='HP_0002326'>TIA</z:hpo> history and <z:hpo ids='HP_0001297'>stroke</z:hpo> mechanism also predict <z:mpath ids='MPATH_124'>infarct</z:mpath> volume in <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
</text></document>